-3%

est. 2Y upside i

HealthcareSeries C

Rank

#1857

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Medium

Cellworks presents a moderate upside opportunity for a job seeker.

Last updated: March 10, 2026

Bull (30%)+150%

Cellworks' biosimulation platform achieves widespread adoption by physicians and payers, leading to significant market penetration in personalized therapy decision support. Successful partnerships with major pharma companies accelerate drug discovery, driving annual revenue to $100M+ by 2028 and justifying a $750M+ valuation at a 7.5x revenue multiple, well above the current $300M.

Base (55%)+30%

Cellworks maintains its strong competitive position in personalized therapy decision support and secures moderate traction in drug discovery services. Revenue grows steadily to $40M-$50M by 2028, leading to an exit valuation of $390M-$450M, reflecting continued execution and market acceptance.

Bear (15%)-50%

Despite its strong technology, Cellworks faces increased competition from well-funded incumbents or new entrants, leading to slower-than-expected market adoption and pricing pressure. Revenue growth stalls at $30M-$35M, resulting in a flat or down round, with a valuation of $150M-$200M, significantly impacting common stock value given the existing preference stack of $54.3M.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $54.3M in liquidation preferences ahead of common shareholders, representing 18.1% of the estimated $300M valuation.

Dilution Risk

moderate

The company, having completed a Series C1 round, may require additional funding rounds before a liquidity event, potentially diluting existing equity holders.

Secondary Liquidity

none

There is no indication of an active secondary market or tender offers for employee equity.

Questions to Ask at the Interview

Strategic questions based on Cellworks's data — designed to show you've done your homework.

  • 1

    “Cellworks' biosimulation platform aims to predict therapy response. How do you differentiate your predictive accuracy and clinical utility from other precision oncology diagnostics companies like Guardant Health or Exact Sciences, especially as they expand their offerings?”

  • 2

    “With an estimated annual revenue of nearly $30M and profitability, what are the key strategic initiatives to scale revenue significantly over the next 2-3 years, particularly in expanding your drug discovery services to pharmaceutical partners?”

  • 3

    “Given the Series C1 funding in 2023 and the capital-intensive nature of biotech, what is the anticipated timeline for a liquidity event (IPO or acquisition), and how does the company plan to manage potential future dilution for common shareholders?”

Community

Valuation Sentiment

Our model estimates -3% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.